Subjects who are hypersensitive to any component of the vaccine or subjects who have shown signs of hypersensitivity after previous administration should not be given the vaccine.

Injection site:

Common

• Mild soreness, indurations, erythema

Rare

• Injection site reactions of moderate to severe intensity

Adverse Reactions

Shanvac-B® can be used for the primary vaccination as well as for booster doses interchangeably with plasma-derived or other rDNA-based Hepatitis B vaccines.

Immunogenicity and Safety of Shanvac-B®

I. Infants & Children

Immunogenicity and safety studies in infants and children demonstrated that Shanvac-B® is immunogenic with a GMT of 218 mIU/mL after 3 dose vaccination.

REFERENCES

For full list of references see reverse side of the leaflet.

Bibliography

JAPI. 2000;17:1125-1129

Email: info@shanthabiotech.co.in

Fax: +91-23234103, 23234133

Adequate human and animal data on use during pregnancy and lactation are available.

Shanvac-B® is contraindicated in individuals who are hypersensitive to any component of the vaccine.

Shanvac-B® should not be given to individuals who have shown signs of hypersensitivity after previous administration.

Shanvac-B® should not be administered subcutaneously in patients with severe bleeding tendencies (e.g. hemophiliacs).

Shanvac-B® is not recommended for the use in patients with severe febrile infections.

Shanvac-B® is not recommended for the use in patients with severe febrile infections.